Loading company…
NATiAS contract-manufactures nucleic acids for pharmaceutical, biotechnology and research applications.
Founded in 2015 and based in Kobe-shi, Japan, NATiAS manufactures nucleic acids, including active pharmaceutical ingredients and diagnostic primers. Its Blockmer® technology is used to shorten synthesis time, and the company also produces nucleic acid intermediates and works on joint development projects. It raised JPY 330 million in Series B funding on March 9, 2022, with Minato Capital, Mitsui Chemicals and TORAY ENGINEERING Co.,Ltd among the investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in